Multiorgan Transplant Program, University of Toronto, Toronto, Canada.
Liver Transplantation and Hepatology Unit, La Fe University Hospital, Universidad de Valencia, Valencia, Spain.
Liver Transpl. 2018 Jun;24(6):831-840. doi: 10.1002/lt.25072.
Given the scarcity of donated organs and the frequency of death on the waiting list, strategies that could improve the available supply of high-quality liver grafts are much needed. Direct-acting antiviral agent (DAA) regimens have proved to be highly effective to treat hepatitis C virus (HCV), even in the setting of posttransplantation. The question arises as to whether transplant communities should consider the utilization of HCV-positive donors into HCV-negative recipients. This review summarizes risk of transmission, treatment options with success rate, and ethical considerations for usage of HCV-positive donors. Liver Transplantation 24 831-840 2018 AASLD.
鉴于捐献器官的稀缺性和等待名单上的死亡频率，非常需要能够提高高质量肝移植物供应的策略。直接作用抗病毒药物 (DAA) 方案已被证明对治疗丙型肝炎病毒 (HCV) 非常有效，即使在移植后也是如此。问题是移植界是否应该考虑将 HCV 阳性供体用于 HCV 阴性受者。这篇综述总结了 HCV 阳性供体的传播风险、成功率的治疗选择和使用的伦理考虑。肝移植 24 831-840 2018 AASLD。
